Technology Access Program Inquiry
Please provide your information and a member of the Singular Genomics team will be in contact with more details about the PX Technology Access Program.
Please provide your information and a member of the Singular Genomics team will be in contact with more details about the PX Technology Access Program.
Dr. Ledbetter is board certified by the American Board of Medical Genetics and Genomics as a clinical genetics laboratory director and built large genetics diagnostics programs throughout his academic career at Baylor College of Medicine, the University of Chicago, and Emory University School of Medicine. He is internationally recognized for his research on the genetic basis of childhood neurodevelopmental disorders, having discovered the genetic cause of Prader-Willi syndrome (1981) and Miller-Dieker syndrome (1983) very early in his career. Since that time, he has made numerous contributions to the translation of new genomics technologies into clinically useful genetic tests for early diagnosis and intervention in autism and related disorders. Dr. Ledbetter served as Executive Vice President and Founding Chief Scientific Officer at Geisinger for 10 years (2010-2020), where he helped lead their MyCode biobank/genomics project – one of the largest in the world. His current research interest includes leveraging longitudinal electronic health information with large-scale DNA sequencing to determine the clinical utility and cost-effectiveness of precision medicine approaches in real-world health system settings.
Dr. Ledbetter currently serves as Chief Clinical & Research Officer at Unified Patient Network, Inc., a start-up company building a massive Precision Medicine database across multiple healthcare systems linking patient EHR and other clinical data sets to clinical whole genome sequence data.
He is a graduate of Tulane University and earned his Ph.D. at the University of Texas-Austin.
Over the past 25 years, Daniel has helped build several highly successful organizations from startup to public companies. He most recently served as the Chief Scientific Officer of Fate Therapeutics (2009 -2021) where he lead the innovation efforts to bring multiple iPSC derived cell therapies to the clinic. Prior to Fate, Dr. Shoemaker was Chief Scientific Officer of ICx Biosystems (2003-2009), a biotechnology firm that developed advanced detection technologies for use in biodefense, cancer and prenatal diagnostics. From 1998 to 2003, Dr. Shoemaker was one of the founding scientists at Rosetta Inpharmatics which developed a novel microarray platform and suite of bioinformatics tools for analyzing large genomic data sets. After being acquired by Merck, Daniel served as Senior Director of Genomics where he was responsible for target discovery. Dr. Shoemaker received his Ph.D. in biochemistry from Stanford University and his B.S. in biochemistry from the University of California, Santa Barbara.
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center. He is a physician-scientist in the Department of Medicine, Division of Hematology/Oncology directing both a translational research program and an NIH-funded research lab. He has focused on cancer immunotherapy for over 20 years and has been involved in both pre-clinical and clinical studies of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors. He has also been involved in multiple first-in-human clinical trials including trials of dendritic cell vaccines, ipilimumab and an adenosine receptor antagonist. Dr. Fong’s research examines the mechanisms that underlie clinical response and resistance to immunotherapies. This work includes tracking antigen-specific T cell responses in treated cancer patients and developing biomarkers that are associated with clinical outcomes. The Cancer Immunotherapy Program that he directs performs early phase and high risk clinical trials across different disease indications. This program also includes a translational laboratory that performs mechanistic studies on samples derived from patients undergoing treatment. Throughout his career, Dr. Fong has received multiple awards including the NIH Outstanding Investigator Award.
Dr. Fong obtained his BA from Columbia and MD from Stanford. He completed internal medicine training at University of Washington, and oncology fellowship and post-doctoral training at Stanford in 2002. He then moved to UCSF as an assistant professor where he is now a distinguished professor. He is an elected member of Alpha Omega Alpha and the American Society for Clinical Investigation. He has over 100 publications in journals including NEJM, Nature, Nature Medicine, Cell, Immunity, and Cancer Discovery. He has served on multiple NIH study sections, the NCI Steering Committees for Genitourinary Cancer (GUSC), the NCI Investigational Drugs (IDSC)-Immunotherapy Task Force, the Department of Defense Prostate Cancer Research Program (PCRP) Vision Setting Committee, and NCI Immuno-oncology Translation Network (IOTN) Steering Committee. He has also served on multiple journal editorial boards including the Journal of Clinical Oncology, Journal of Immunotherapy of Cancer, and Cancer Immunology Research.
Dr. Fong cofounded several companies including FWB LLC (acquired by Streamlogic), Techbargains.com LLC (acquired by Exponential), and Keyhole Therapeutics. He has ongoing research collaborations with Abbvie, Amgen, Bavarian Nordic, Bristol Myer Squibb, Dendreon, Janssen, Merck, and Roche/Genentech. He sits on the steering committee of the Roche/Genentech imCORE network. He also has served on multiple scientific advisory boards including Alector (ALEC), Atreca (BCEL), Bioatla (BCAB), Bolt (BOLT), Ideaya (IDYA), Innovent (IVBXF) Nutcracker, RAPT (RAPT), Senti, Soteria, TeneoBio (acquired by Amgen), and Xyphos (acquired by Astellas).
